Shares of ChemoCentryx Inc. (NASDAQ:CCXI) were down 0.4% during mid-day trading on Friday . The company traded as low as $4.75 and last traded at $4.80, with a volume of 79,560 shares traded. The stock had previously closed at $4.82.

A number of analysts recently issued reports on CCXI shares. Zacks Investment Research upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research note on Wednesday, April 27th. Cowen and Company reiterated a “hold” rating on shares of ChemoCentryx in a research note on Monday, March 14th.

The firm’s 50 day moving average is $4.84 and its 200-day moving average is $3.96. The firm’s market capitalization is $212.59 million.

ChemoCentryx (NASDAQ:CCXI) last released its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by $0.07. Equities research analysts forecast that ChemoCentryx Inc. will post ($0.35) EPS for the current year.

In related news, Director Thomas A. Edwards bought 50,000 shares of the firm’s stock in a transaction on Tuesday, May 17th. The stock was purchased at an average price of $4.05 per share, with a total value of $202,500.00. Following the completion of the transaction, the director now directly owns 91,977 shares of the company’s stock, valued at $372,506.85. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Geoffrey M. Parker bought 40,000 shares of the firm’s stock in a transaction on Friday, May 13th. The shares were bought at an average cost of $4.03 per share, with a total value of $161,200.00. Following the transaction, the director now directly owns 13,514 shares of the company’s stock, valued at $54,461.42. The disclosure for this purchase can be found here.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.